Eiger Bio's Avexitide Reduces Glucose Infusion Requirements To Maintain Normal Glucose Levels In Neonates, Infants

  • Eiger BioPharmaceuticals Inc EIGR announced an oral poster presentation of Phase 2 study results of Avexitide in congenital hyperinsulinism (HI) at the American Diabetes Association Scientific Session.  
  • HI is an ultra-rare, life-threatening pediatric disorder of persistent hypoglycemia that results in irreversible brain damage in up to 50% of children.  
  • Avexitide significantly reduced glucose infusion rate (GIR) when evaluated across dose levels, with dose-dependent improvements observed.  
  • Avexitide 100, 200, and 1,000 pmol/kg/min ascending doses demonstrated 1.3 (15%), 2.9 (24%), and 4.3 (56%) mg/kg/min reductions in GIR relative to placebo, respectively, and entirely abolished the glucose requirement in 50% of patients at the top dose.  
  • Avexitide was well-tolerated in this study. Adverse events were typically mild in severity and transient, and there were no serious adverse events.
  • The company plans to be Phase 3 ready as early as 2022.
  • Price Action: EIGR shares are up 7.9% at $9.36 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsHealth CareSmall CapGeneralBriefshyperinsulinism
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!